Effect of cardiovascular comorbidities on disease severity and quality of life in Patients with acute exacerbation of non-cystic fibrosis bronchiectasis
The study will include patients with bronchiectasis, and in an attempt to correlate the effect and burden of cardiovascular comorbidities in those patients, we will study the quality of life in those patients in comparison to the control group ( patients with bronchiectasis and without any other comorbidities) using SF-36 quality of life questionnaire. We will also study the inflammatory markers in both groups using D-dimer, BNP, and CRP and correlate them with the frequency of hospital admission, the severity of symptoms, and the general health state.
Study Type
OBSERVATIONAL
Enrollment
30
echocardiographic study of both groups
Assiut unviresty - Faculty of Medicine
Asyut, Egypt
RECRUITINGassessment of BNP (Brain natriuretic peptide) pg/ml levels in patients with bronchiectasis and cardiovascular comorbidities.
Serum BNP (Brain natriuretic peptide) pg/ml will be compared in both groups.
Time frame: March 2023 to September 2023
Assessment of Quality of life in patients and control groups using The Short Form (36) Health Survey (SF-36)
The Short Form (36) Health Survey will be performed in both groups. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
Time frame: March 2023 to September 2023
Hospitalization frequency in patient group compared to control group.
Number of hospital admission in the last year will be compared in both groups.
Time frame: March 2023 to September 2023
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.